104 related articles for article (PubMed ID: 3340049)
1. Low-dose enteric-coated aspirin as an antiplatelet preparation.
McLeod LJ; Roberts MS; Seville PR
Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
[No Abstract] [Full Text] [Related]
2. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers.
Coleman JL; Alberts MJ
Am J Cardiol; 2006 Sep; 98(6):838-41. PubMed ID: 16950199
[TBL] [Abstract][Full Text] [Related]
3. Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers.
Dharmasaroja PA; Sae-Lim S
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):649-52. PubMed ID: 20689403
[TBL] [Abstract][Full Text] [Related]
4. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
Antonino MJ; Coppolecchia R; Mahla E; Bliden KP; Tantry US; Gurbel PA
Thromb Res; 2010 Nov; 126(5):384-5. PubMed ID: 19446864
[TBL] [Abstract][Full Text] [Related]
6. Effects of enteric-coated, low-dose aspirin on parameters of platelet function.
Van Hecken A; Juliano ML; Depré M; De Lepeleire I; Arnout J; Dynder A; Wildonger L; Petty KJ; Gottesdiener K; De Hoon JN
Aliment Pharmacol Ther; 2002 Sep; 16(9):1683-8. PubMed ID: 12197849
[TBL] [Abstract][Full Text] [Related]
7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
8. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
[TBL] [Abstract][Full Text] [Related]
9. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
10. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
11. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
12. Peripheral venous plasma aspirin concentrations and platelet aggregation inhibition produced by enteric-coated aspirin formulations.
Brandon RA; Emmett JA; Eadie MJ; Curran AC; Bunce IH
Thromb Haemost; 1986 Apr; 55(2):222-7. PubMed ID: 3715789
[TBL] [Abstract][Full Text] [Related]
13. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery.
Vanags D; Rodgers SE; Lloyd JV; Bochner F
Thromb Res; 1990 Sep; 59(6):995-1005. PubMed ID: 2264023
[TBL] [Abstract][Full Text] [Related]
14. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
[TBL] [Abstract][Full Text] [Related]
15. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs.
Takada M; Fukumoto K; Shibakawa M
J Clin Pharm Ther; 2004 Apr; 29(2):183-7. PubMed ID: 15068408
[TBL] [Abstract][Full Text] [Related]
16. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
Schiff M; Hochberg MC; Oldenhof J; Brune K
Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
[TBL] [Abstract][Full Text] [Related]
17. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function.
Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G
J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
20. In brief: enteric-coated aspirin as an antiplatelet drug.
Med Lett Drugs Ther; 2014 Apr; 56(1441):36. PubMed ID: 24759295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
